Healthcare Stocks Dogged by U.S. Policy Concerns
Large biopharma names are undervalued while device and diagnostic industries look pricey.
Source: morningstar.com
Stay updated with breaking news from Value Uncertainty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Large biopharma names are undervalued while device and diagnostic industries look pricey.
Inflation weighs on earnings, balance sheets, and real yields, but growth opportunities remain.
After a strong performance in 2021, the sector offers little opportunity today.
Do any of this year’s top performers have gas left in the tank for 2022?
Areas hurt most by the pandemic have rebounded.